Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 901920 of 20,252 grants

Active OTHER RESEARCH-RELATED
Cancer Genomics: Integrative and Scalable Solutions in R/Bioconductor
NATIONAL CANCER INSTITUTE Graduate School of Public Health and Hea... United States 2024 – 2029

Abstract Bioconductor is a crucial resource for statistical analysis and data management in cancer genomics research, providing more than 2,200 open-source software and data packag...

$8.47M
USD
Active OTHER RESEARCH-RELATED
Targeted delivery of a VEGF‐blocking scFv by CD70 CAR‐T cells to enhance anti‐tumor activity in renal cell carcinoma
NATIONAL CANCER INSTITUTE Massachusetts General Hospital United States 2024 – 2029

PROJECT SUMMARY Although chimeric antigen receptor (CAR)-T cells drive dramatic and durable remissions in patients with B-cell malignancies, responses in solid tumors have been mor...

$2.98M
USD
Active TRAINING, INDIVIDUAL
Optimizing treatment decisions and quality-adjusted life years through improved lung cancer staging
NATIONAL CANCER INSTITUTE Massachusetts General Hospital United States 2024 – 2026

PROJECT SUMMARY The number of patients with potentially curable, stage I-III non-small cell lung cancer (NSCLC) is increasing, and appropriate treatment selection depends upon the...

$812.6K
USD
Active NON-SBIR/STTR RPGS
Structure-guided cancer immunotherapy design with HLA-Arena and CrossDome
NATIONAL CANCER INSTITUTE University of Houston United States 2024 – 2026

Project Summary The broader use of T-cell-based therapies is still hindered by challenges related to the identification of peptide- targets that are both immunogenic (capable of act...

$4.15M
USD
Active NON-SBIR/STTR RPGS
Dissecting the role of germline genetic variation and viral exposures as determinants of hematological disease predisposition
NATIONAL CANCER INSTITUTE Van Andel Research Institute United States 2024 – 2026

ABSTRACT The role of germline genetic variation and viral infection in development and progression has been studied extensively in adult tumors and autoimmune disease. Less attenti...

$3.36M
USD
Completed OTHER RESEARCH-RELATED
TGF-β Superfamily Conference: Signaling in Development and Disease
NATIONAL CANCER INSTITUTE Federation of Amer Soc for Exper Biology United States 2024 – 2025

Abstract The FASEB SRC TGF-β Superfamily: Signaling in Development and Disease Conference in 2024 (hereafter “TGF-β 2024”) will bring together investigators who are leaders in a va...

$200K
USD
Active NON-SBIR/STTR RPGS
Addressing financial hardship in adolescent and young adult cancer survivors: Efficacy and implementation of a multilevel intervention in community-based oncology practices
NATIONAL CANCER INSTITUTE Wake Forest University Health Sciences United States 2024 – 2029

Project Summary Adolescent and young adult cancer survivors (AYAs; ages 15-39-years) are an important underserved group at risk for significant financial hardship. There are nearly...

$7M
USD
Completed OTHER RESEARCH-RELATED
2024 Radionuclide Theranostics for the Management of Cancer Gordon Research Conference and Gordon Research Seminar
NATIONAL CANCER INSTITUTE Gordon Research Conferences United States 2024 – 2024

Project Summary/Abstract The Gordon Research Conference (GRC) and Symposium (GRS) for "Radionuclide Theranostics for the Management of Cancer", a rapidly emerging field i...

$50K
USD
Active NON-SBIR/STTR RPGS
Innovations in diagnosis for lymphadenopathy across HIV Centers of Excellence in Malawi
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2024 – 2029

ABSTRACT In SSA, deaths occur in 5-10% of PLWH during the first year after initiating antiretroviral therapy (ART) and causes for these early deaths are not well elucidated in most...

$5.44M
USD
Active SBIR-STTR RPGS
Microsphere-based formulation of dolcanatide to prevent colon carcinogenesis
NATIONAL CANCER INSTITUTE Nous Biosciences Inc United States 2024 – 2026

Abstract Colorectal cancer (CRC) ranks third among newly diagnosed cancers in the United States, and it is the second most common cause of cancer mortality. Individuals with inflam...

$3.09M
USD
Completed SBIR-STTR RPGS
Synthetic Biology for Splice Modulating Polyketides
NATIONAL CANCER INSTITUTE Varigen Biosciences Corporation United States 2024 – 2025

Project Summary. Natural product-derived RNA splice modulators are being developed for the treatment of acute myeloid leukemia as well as other cancers. As natural products with co...

$2.97M
USD
Completed SBIR-STTR RPGS
Immunoassay for Measuring Mutation Activated Kinases Across Multiple Cell Signaling Pathways
NATIONAL CANCER INSTITUTE Adeptrix Corporation United States 2024 – 2025

ABSTRACT Due to the vast number of potential drug combinations, “testing them all” in clinical trials is impossible, putting pressure on preclinical research to find the most promi...

$2.95M
USD
Active NON-SBIR/STTR RPGS
Augmenting focused ultrasound-mediated drug delivery to brain tumors with vascular normalization
NATIONAL CANCER INSTITUTE University of Virginia United States 2024 – 2026

The blood-tumor barrier (BTB) hinders the delivery and penetration of systemically administered therapeutic agents into the brain tumor microenvironment. The BTB is created by dila...

$3.99M
USD
Active NON-SBIR/STTR RPGS
Develop universal CAR macrophage cell therapy for pancreatic cancer
NATIONAL CANCER INSTITUTE Rutgers Biomedical and Health Sciences United States 2024 – 2026

SUMMARY/ABSTRACT Macrophages (Mφs) are innate immune cells, phagocytes and professional antigen presenting cells, which are crucial for tissue homeostasis and adaptive immune respo...

$4.04M
USD
Active NON-SBIR/STTR RPGS
Engineering bZIP family transcription factors for therapeutic T-cell persistence and effector function
NATIONAL CANCER INSTITUTE Baylor College of Medicine United States 2024 – 2029

PROJECT SUMMARY Cancer immunotherapy using T cells engineered with a chimeric antigen receptor or T-cell receptor directed against cancer antigens is a promising new therapeutic mo...

$4.83M
USD
Active NON-SBIR/STTR RPGS
High-throughput assessment of chemotherapy-induced cardiotoxicity in 3D human cardiomyocytes
NATIONAL CANCER INSTITUTE Emory University United States 2024 – 2026

High-throughput assessment of chemotherapy-induced cardiotoxicity in human cardiospheres Project Summary Chemotherapeutic agents including both traditional drugs (e.g., anthracycli...

$4.02M
USD
Active NON-SBIR/STTR RPGS
Randomized Controlled Trial of a Hybrid-Delivered Cognitive Behavioral Symptom Management and Activity Coaching Intervention for Stem Cell Transplant Patients
NATIONAL CANCER INSTITUTE Duke University United States 2024 – 2029

Our objective is to use novel mobile health (mHealth) behavioral intervention approaches to enable patients who have undergone hematopoietic stem cell transplant (HCT) to effective...

$5.62M
USD
Active NON-SBIR/STTR RPGS
Development of Chimeric Antigen Receptor Phagocytes Against Glioblastoma
NATIONAL CANCER INSTITUTE University of Colorado Denver United States 2024 – 2029

Project Abstract: Pediatric HGGs comprise glioblastoma [glioblastoma multiforme (GBM)], anaplastic astrocytoma, and diffuse intrinsic pontine glioma (DIPG) and collectively are the...

$4.48M
USD
Active NON-SBIR/STTR RPGS
Development of fast diffusion magnetic resonance fingerprinting of the prostate to avoid unnecessary biopsies
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2024 – 2029

Abstract The most common malignancy for men in the western world is Prostate cancer (PCa), with a predicted 288,300 new cases and 34,700 specific deaths in 2023. With recent develo...

$5.98M
USD
Active NON-SBIR/STTR RPGS
Predicting Endocrine Therapy Response In Male Breast Tumors
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2024 – 2029

PROJECT SUMMARY/ABSTRACT Male breast cancer is critically understudied due to both the rarity of the disease and the exclusion of men from breast cancer trials leading to a signifi...

$6.05M
USD